Aethlon Medical Acquires Strategic Cancer Therapy Patent.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has acquired world-wide rights to a patent submission entitled, "De-repression of anticancer immunity through extracorporeal removal of microvesicular particles." Under the patent, assigned to Aethlon Medical by London Health Science Center Research Inc., the Aethlon Hemopurifier(TM) would address a significant unmet clinical need in cancer therapy by reducing the presence of tumor-secreted microvesicles that inhibit the immune system from responding in cancer patients.

Microvesicular particles are small enough to be separated from circulation by the Hemopurifier(TM), and they have glycosylated surfaces that are the binding targets of affinity capture agents immobilized in the Hemopurifer(TM) to capture viral pathogens. As such, the Hemopurifer(TM) that has progressed through animal studies, biocompatibility testing, multiple invitro virus studies, and demonstrated safety and virus capture in a human clinical study, may also offer an important clinical benefit to those afflicted with cancer.

At present, Aethlon has submitted a preliminary Investigational Device Exemption with The Food and Drug Administration (FDA) related to the use of the Hemopurifier(TM) in the United States as a broad-spectrum countermeasure against bioweapon threats and naturally evolving pathogens, including virulent influenza. The Company also plans to continue human safety and efficacy testing of the Hemopurifier(TM) in India.

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.